Welcome to our dedicated page for DOCGO SEC filings (Ticker: DCGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing DocGo’s multi-segment disclosures can feel like treating a patient without a chart. The company’s mobile health contracts, ambulance fleet costs, and virtual-care metrics often sit side-by-side in a single document. Whether you’re hunting for how a new city contract shows up in an 8-K or comparing Mobile Health margins across quarters, the details are deep. That’s why investors search for "DocGo SEC filings explained simply"—and why Stock Titan starts by translating the technical language.
Our AI reads every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR. Within seconds you’ll see
- AI-powered summaries that surface segment revenue, payer mix, and fleet expansion costs
- Real-time alerts on "DocGo Form 4 insider transactions real-time" for fast trade monitoring
- Expert notes that turn complex healthcare reimbursement tables into plain English
Investors routinely ask about "DocGo insider trading Form 4 transactions" and "DocGo proxy statement executive compensation" to gauge management’s incentives. Others want the "DocGo annual report 10-K simplified" or "DocGo 8-K material events explained" to understand how new municipal deployments could shift revenue. By "understanding DocGo SEC documents with AI," you’ll pinpoint which units drive growth, track "DocGo executive stock transactions Form 4," and monitor cash burn tied to ambulance acquisitions—information that can influence valuation well before the next earnings call.
DocGo (DCGO) reported a sharp year-over-year contraction in Q3 2025. Revenue was $70.8M versus $138.7M a year ago, driven by a steep drop in Mobile Health Services to $20.7M from $90.7M, while Transportation Services delivered $50.1M vs $48.0M. The company posted a net loss attributable to stockholders of $27.8M compared with $5.5M income a year earlier, reflecting lower volume and non-cash charges.
Management recorded a $8.7M goodwill impairment tied to the Rapid Temps reporting unit and a $8.0M impairment of finite‑lived intangibles in Mobile Health Services. For the nine months, revenue was $247.3M vs $495.7M, with a $48.3M loss to stockholders. Cash from operations was $44.9M, supported by a large reduction in accounts receivable. The balance sheet showed cash and cash equivalents of $73.4M, total assets of $353.8M, and no outstanding line of credit at quarter‑end. Shares outstanding were 97,813,372 as of November 7, 2025.
DocGo Inc. (DCGO) furnished its earnings materials for the quarter ended September 30, 2025. The company issued a press release and provided supplemental non-GAAP metrics, including adjusted gross margin and adjusted EBITDA contribution margin, as supporting materials.
Management scheduled a conference call and webcast at 5:00 p.m. Eastern Time on November 10, 2025 to discuss results. The materials were furnished, not filed, and include Exhibit 99.1 (Press Release) and Exhibit 99.2 (Non-GAAP Financial Information).
DocGo Inc. filed an amended Form 8‑K to attach the Merger Agreement for its completed acquisition of SteadyMD, Inc. via subsidiary Ambulnz Holdings, LLC. The transaction totals up to $25 million, consisting of $12.5 million in cash paid at closing and up to $12.5 million as a contingent earn‑out payable in cash or equity at the Company’s election, tied to performance conditions. The closing payment is subject to customary post‑closing adjustments for working capital, debt, and transaction expenses.
Upon filing a Certificate of Merger on October 20, 2025, SteadyMD merged into STMD Merger Company, LLC, which survived; all shares, options, and warrants of the Acquired Company were canceled. This amendment adds the Merger Agreement as Exhibit 2.1 and does not change other prior disclosures.
DocGo Inc. announced that its wholly owned subsidiary, Ambulnz Holdings, completed the acquisition of SteadyMD, Inc. via a merger on October 20, 2025. The deal carries an aggregate purchase price of up to $25 million, including $12.5 million in cash paid at closing and up to $12.5 million in contingent earn-out, payable in cash or equity at the company’s election if specified performance conditions are met. The closing cash amount is subject to customary post‑closing adjustments for working capital, indebtedness, and transaction expenses.
Upon filing the certificate of merger, SteadyMD merged into a DocGo subsidiary with the subsidiary surviving, and all SteadyMD shares, options, and warrants were canceled under the agreement. DocGo will host a conference call and webcast on October 21, 2025 at 11:00 a.m. ET to discuss the transaction.
Stephen K. Klasko, a director of DocGo Inc. (DCGO), was granted 100,000 restricted stock units (RSUs) under the Issuer's 2021 Stock Incentive Plan. Each RSU represents the right to receive one share of DocGo common stock upon vesting.
The RSUs vest on September 10, 2026 subject to the terms of the plan. The reported grant carried a $0 per-share price and, after the grant, Mr. Klasko is reported to beneficially own 115,000 shares. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of DOCGO (DCGO)?
What is the market cap of DOCGO (DCGO)?
